You are here

  • Home
  • Archive
  • Volume 29, Issue 4
  • Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study

Article metrics

Article menu
Download PDFPDF
Original research
Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study

 

Online download statistics by month:

Online download statistics by month: October 2020 to March 2024

AbstractFullPdf
Oct 20204201213
Nov 202036755
Dec 20207311
Jan 202113321
Feb 202113111
Mar 202112110
Apr 202113300
May 20215100
Jun 20211211
Jul 20211000
Aug 2021823
Sep 2021901
Oct 202116711
Nov 202124731
Dec 202123311
Jan 202232942
Feb 202225200
Mar 202238700
Apr 202228613
May 202239511
Jun 20225721311
Jul 2022780136
Aug 2022612139
Sep 202224976
Oct 202221413
Nov 202227185
Dec 202212900
Jan 202318411
Feb 202315822
Mar 202316952
Apr 202317612
May 202311600
Jun 202315411
Jul 20235600
Aug 20235600
Sep 20233632
Oct 202310300
Nov 202319410
Dec 20236301
Jan 202418316
Feb 20248307
Mar 20247020
Total839210899